Rad51L3-RFFL: A Potential Drug Target and Biomarker (G100529207)

Target Name: RAD51L3-RFFL

NCBI ID: G100529207

RAD51L3-RFFL

Other Name(s): RAD51L3-RFFL readthrough

Rad51L3-RFFL: A Potential Drug Target and Biomarker

Rad51L3-RFFL (respiratory factor-like protein L3) is a protein that is expressed in various tissues of the body, including the lungs, heart, kidneys, and intestines. It is a key regulator of cell proliferation and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The rad51 gene is a member of the TOW gene family, which is known for the regulation of cell growth and differentiation. The rad51 gene encodes a protein that contains a unique domain that is similar to that of the transcription factor RFFL. This domain is responsible for the protein's ability to interact with DNA and regulate gene expression.

Rad51L3-RFFL has been shown to play a role in a number of important biological processes, including cell proliferation, apoptosis, and inflammation. It has also been shown to be involved in the development and progression of a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

As a potential drug target, Rad51L3-RFFL is of interest because of its ability to interact with a variety of different molecules and because it has been shown to be involved in the development and progression of a number of diseases. This makes it an attractive target for research and development of new treatments.

The rad51 gene is located on chromosome 19 and has been shown to encode a protein of 21 kDa. The protein is composed of a unique N-terminal domain, a catalytic domain, and a C-terminal domain. The N-terminal domain is responsible for the protein's ability to interact with DNA and the catalytic domain is responsible for the protein's ability to catalyze the transfer of a phosphate group to DNA. The C-terminal domain is responsible for the protein's ability to interact with and regulate the activity of other proteins.

The rad51 gene has been shown to encode a protein that is similar to that of the transcription factor RFFL. RFFL is a protein that is expressed in a variety of tissues and is involved in the regulation of gene expression. It is composed of a unique N-terminal domain, a catalytic domain, and a C-terminal domain. The N-terminal domain is responsible for the protein's ability to interact with DNA and the catalytic domain is responsible for the protein's ability to catalyze the transfer of a phosphate group to DNA. The C-terminal domain is responsible for the protein's ability to interact with and regulate the activity of other proteins.

Rad51L3-RFFL has been shown to play a role in the regulation of gene expression and has been implicated in the development and progression of a number of diseases. For example, studies have shown that high levels of Rad51L3-RFFL are associated with the development of cancer and that inhibiting its activity can lead to the regression of cancer tumors.

In addition to its role in cancer, Rad51L3-RFFL is also implicated in the development and progression of other diseases, including neurodegenerative diseases and autoimmune disorders. For example, studies have shown that Rad51L3-RFFL is involved in the development of neurodegenerative diseases, such as Alzheimer's disease, and that inhibiting its activity can lead to the regression of these diseases.

As a potential drug target, Rad51L3-RFFL is of interest because of its ability to interact with a variety of different molecules and because it has been shown to play a role in the development and progression of a number of diseases. This makes it an attractive target for

Protein Name: RAD51L3-RFFL Readthrough

The "RAD51L3-RFFL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAD51L3-RFFL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets